|
LIVE WEBINAR: Thursday, June 29, 2023, 5:00 PM – 6:00 PM Eastern Time
Inside the Issue: Optimizing the Management of Metastatic Urothelial Bladder CancerA CME/MOC-Accredited Live WebinarJoin us on Thursday, June 29th for this CME/MOC-accredited webinar Faculty
Terence Friedlander, MD Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair Chief, Division of Hematology/Oncology Zuckerberg San Francisco General Hospital Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California
Petros Grivas, MD, PhD
Professor, Department of Medicine Division of Oncology Clinical Director, Genitourinary Cancers Program University of Washington Professor, Clinical Research Division Fred Hutchinson Cancer Center Seattle, Washington Moderator Neil Love, MD Research To Practice Miami, Florida Thursday, June 29, 2023 Topics to Be Discussed
Target Audience
CE Credit FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Friedlander — Advisory Committee: Aadi Bioscience, Astellas, Seagen Inc; Consulting Agreement: Merck; Contracted Research: Bristol Myers Squibb, Roche Laboratories Inc, Seagen Inc, Trishula Therapeutics Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Dr Grivas — Consulting Agreements: 4D Pharma PLC, Aadi Bioscience, Asieris Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis Inc, Fresenius Kabi AG, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, ImmunityBio, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Lucence, Merck KgaA, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Pfizer Inc, PureTech Health, QED Therapeutics, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, Silverback Therapeutics Inc, Strata Oncology, UroGen Pharma; Contracted Research: Acrivon Therapeutics Inc, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, G1 Therapeutics Inc, Gilead Sciences Inc, GSK, Merck KGaA, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Pfizer Inc, QED Therapeutics; Data and Safety Monitoring Board/Committee: Bristol Myers Squibb.SURVEY PARTICIPANTS — Shilpa Gupta, MD — Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Foundation Medicine, Gilead Sciences Inc, Guardant Health, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Seagen Inc; Consulting Agreements: Bristol Myers Squibb, EMD Serono Inc, Foundation Medicine, Merck; Contracted Research: Bristol Myers Squibb, EMD Serono Inc, Exelixis Inc, Gilead Sciences Inc, Merck, Moderna, Novartis, Pfizer Inc, QED Therapeutics, Roche Laboratories Inc; Speakers Bureau: Bristol Myers Squibb, Gilead Sciences Inc, Seagen Inc; Stock Options/Ownership – Public Company: BioNTech SE, Moderna. Daniel P Petrylak, MD — Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Exelixis Inc, Gilead Sciences Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, Monopteros Therapeutics, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Agensys Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Endocyte Inc, Ferring Pharmaceuticals, Genentech, a member of the Roche Group, Gilead Sciences Inc, Innocrin Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Mirati Therapeutics Inc, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, Sanofi, Seagen Inc. Elizabeth R Plimack, MD, MS — Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bristol Myers Squibb, Calithera Biosciences, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, IMV Inc, Janssen Biotech Inc, MEI Pharma Inc, Merck, Natera Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Contracted Research: Astellas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Merck; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Infinity Pharmaceuticals Inc, Pfizer Inc. Guru P Sonpavde, MD — Advisory Committee: Astellas, Bicycle Therapeutics, Bristol Myers Squibb, EMD Serono Inc, G1 Therapeutics Inc, Gilead Sciences Inc, IMV Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lucence, Merck, Pfizer Inc, Scholar Rock, Seagen Inc, Tempus; Consulting Agreements: Merck, Servier Pharmaceuticals LLC, Syapse; Contracted Research: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Gilead Sciences Inc, Helsinn Healthcare SA, Jazz Pharmaceuticals Inc, Lucence, Sanofi; Data and Safety Monitoring Board/Committee: Mereo BioPharma; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Exelixis Inc, Gilead Sciences Inc, Janssen Biotech Inc, Natera Inc, Seagen Inc; Nonrelevant Financial Relationship: Informação Brasileira de Oncologia Ltda, Myriad Genetic Laboratories Inc (spouse employment), Onviv, PracticeUpdate, UptoDate, Vial. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Astellas and Seagen Inc, Gilead Sciences Inc, and Merck. |